New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
10:17 EDTBUD, EXPE, WMS, YOKU, NYT, WSFS, BKR, HSY, SCHW, CMA, CLWR, WCC, MRK, GOOG, TIF, WMT, VOD, LF, CVXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Charles Schwab (SCHW) downgraded to Neutral from Buy at UBS... Chevron (CVX) downgraded to Neutral from Buy at UBS... Comfort Systems USA (FIX) downgraded to Hold from Buy at BB&T... Google (GOOG) downgraded to Market Perform from Outperform at BMO Capital... Hershey (HSY) downgraded to Neutral from Conviction Buy at Goldman... LeapFrog (LF) downgraded to Buy from Strong Buy at Ascendiant Capital... Merck (MRK) downgraded to Underweight from Equal Weight at Morgan Stanley... Michael Baker (BKR) downgraded to Hold from Buy at KeyBanc... Vodafone (VOD) downgraded to Neutral from Buy at Citigroup... WESCO (WCC) downgraded to Neutral from Buy at UBS... WSFS Financial (WSFS) downgraded to Neutral from Buy at Janney Capital... Wal-Mart (WMT) downgraded to Neutral from Overweight at JPMorgan... Clearwire (CLWR) downgraded to Underperform from Neutral at DA Davidson... New York Times (NYT) downgraded to Sell from Neutral at Lazard Capital... Tiffany (TIF) downgraded to Neutral from Buy at Monness Crespi... Comerica (CMA) downgraded to Neutral from Long-Term Buy at Hilliard Lyons... Expedia (EXPE) downgraded to Neutral from Buy at Monness Crespi... Guess (GES) downgraded to Underperform from Neutral at Buckingham... Youku Tudou (YOKU) downgraded to Sell from Hold at Maxim... WMS Industries (WMS) downgraded to Hold from Buy at Stifel Nicolaus... AB InBev (BUD) downgraded to Neutral from Buy at BofA/Merrill.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
September 24, 2015
07:24 EDTGOOGWPP CEO: Google needs to weed out 'fake' online ad views, FT reports
Subscribe for More Information
06:59 EDTGOOGFacebook and Google more 'Yelp-like' than ever, says Northland
Northland analyst Darren Aftahi says Facebook (FB), Google (GOOG, GOOGL) and (AMZN) have recently added new features that focus on improved local search as well as tools enabling easier business-consumer communication. Facebook and Google are now more "Yelp-like" than ever, Aftahi tells investors in a research note. And while Apple's (AAPL) new "swipe right" feature could drive a near-term surge in Yelp (YELP) app downloads, it may translate into lower engagement on the Yelp app over longer term, the analyst argues. He remains cautious on Yelp's growth prospects and cut his price target for the stock to $17.75 from $21.50. Shares of the local business review site closed yesterday down 25c to $23.10. Aftahi has an Underperform rating on the stock, his firm's equivalent of a sell.
06:23 EDTBUDHeineken, Carslberg won't benefit from SABMiller-AB InBev merger, WSJ says
Brewers Heineken (HEINY) and Carlsberg will not likely see any benefit from a proposed merger of SABMiller (SBMRY) and AB InBev (BUD), the Wall Street Journal reports. Analysts have suggested that there are a few takeover opportunities for the two brewers as part of a successful AB InBev takeover of SABMiller, the report says. If options do arise, Heineken would have more to explore than Carlsberg since it is larger and more profitable, the report says. Still, some believe Molson Coors (TAP) is seen as the most likely buyer of any assets from SABMiller, including its stake in their joint venture MillerCoors, the report says. Reference Link
06:08 EDTGOOGSamsung Pay has over $30M in accumulated transaction volume in first month
Subscribe for More Information
September 23, 2015
18:14 EDTWMTWal-Mart seeks 2%-6% cuts on China-made goods from suppliers, Reuters says
Subscribe for More Information
18:06 EDTWMTWal-Mart seeks 2%-6% cuts on China-made goods from suppliers, Reuters says
12:18 EDTBUDAnheuser-Busch to acquire craft brewer Golden Road Brewing
Subscribe for More Information
08:50 EDTMRKProvectus initiates Phase 1b/2 trial of PV-10 combo with Pembrolizumab
Provectus Biopharmaceuticals (PVCT) announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma. Pembrolizumab, also known as Keytruda, a product of Merck (MRK), is an immune checkpoint inhibitor approved for treatment of patients with advanced or unresectable melanoma. PV-10 is Provectus's novel investigational drug for cancer that is injected into solid tumors. It is currently undergoing Phase 3 clinical testing in patients with Stage III melanoma. Clinical testing under the new Phase 1b/2 protocol is expected to commence before the end of the year. The FDA granted accelerated approval to pembrolizumab in September 2014, making it the first FDA-approved anti-PD-1 immune checkpoint inhibitor. Because pembrolizumab is already FDA-approved, Provectus can commence this study with or without assistance of a partner.
05:31 EDTCVXExxon Mobil initiated with an Underperform at Macquarie (yesterday)
Subscribe for More Information
September 22, 2015
17:23 EDTGOOGGoogle begins conducting business briefings with analysts, WSJ says
Subscribe for More Information
17:06 EDTGOOGGoogle charges for YouTube ads viewed by bots, Financial Times says
Google has been charging advertisers for YouTube ads even those advertisements were viewed by "robot" computers rather than human beings, reports the Financial Times, citing a study by a group of European researchers. In one example, the research group's "bots" visited two particular YouTube videos 150 times, and Google's AdWords service subsequently charged for 91 of those video views, according to the report. Google told the publication it will contact the group to discuss the results. Reference Link
13:13 EDTCVXChevron initiated with an Underperform at Macquarie
Subscribe for More Information
12:13 EDTBKRMichael Baker selected for architectual, engineering services contract for AFCEC
Michael Baker International, a global leader in engineering, consulting, planning, technical and professional services, is serving as a prime contractor for the U.S. Air Force Civil Engineer Center for the first time. The company is among a group of firms to be awarded the Architect-Engineer 2013 Design and Construction Services contract, which represents $950M engineering and design work to be performed on military installations worldwide through 2022. The agreement allows Michael Baker experts in engineering, design, IT, geographic information systems and other areas to bid on a wide array of projects in support of the U.S. Air Force. This includes the development of comprehensive engineering and design plans for the modernization of operational facilities and the construction and renovation of military family housing.
10:59 EDTLFLeapFrog management to meet with Sterne Agee CRT
Subscribe for More Information
10:45 EDTWMTReimbursement pressure on drug stores should moderate, says Cleveland Research
Cleveland Research analysts Rob Eich and Rob Stuyck said the firm's work indicates that stepdown reimbursement rates will be more manageable for drug store operators and that generic inflation will be less of a headwind for the group in FY16. However, Direct and Indirect Remuneration clauses will still be a source of margin pressure, the firm said, noting that several payers will be introducing a DIR next year. Cleveland Research has Neutral ratings on CVS (CVS), Walgreens (WBA), Rite Aid (RAD) and Wal-Mart (WMT).
09:09 EDTGOOGFrontier says adds Nest cam, Nest Protect to product offerings
Subscribe for More Information
08:43 EDTEXPEExpedia price target raised to $150 from $135 at Cowen
Subscribe for More Information
07:43 EDTMRKDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:15 EDTGOOGCloudFlare raises $110M from consortium of Google, Microsoft, others
Subscribe for More Information
06:19 EDTMRKClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use